HI
PACB icon

HBK Investments’s Pacific Biosciences PACB Stock Holding History

HBK Investments’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-168,500
Closed -$1.19M – 953
2016
Q2 		$1.19M Buy
+168,500
New +$1.54M 0.01% 532

Other funds holding PACB

MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HBK Investments's PACB Position: Q3 2016 in Review

HBK Investments sold out of Pacific Biosciences (PACB) in Q3 2016, closing a stake of 168,500 shares — an estimated $1.19M sold.

HBK Investments first reported a position in PACB in Q2 2016 and held it in 1 quarter. The position peaked at $1.19M in Q2 2016. 128 funds tracked by Wall St. Rank hold PACB as of Q3 2016.

  • HBK Investments reported no remaining Pacific Biosciences position as of Q3 2016 after selling out during the quarter.
  • HBK Investments sold 168,500 Pacific Biosciences shares in Q3 2016, an estimated $1.19M.
  • HBK Investments first reported a position in Pacific Biosciences in Q2 2016 and held it in 1 quarter.
  • HBK Investments's Pacific Biosciences position peaked at $1.19M in Q2 2016.
  • 128 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2016.

Based on HBK Investments's 13F filing for Q3 2016, filed 14 Nov 2016.